Loading organizations...
§ Private Profile · Marlborough, MA, USA
Medical device company developing the Sapphire II System for non-invasive, early Alzheimer's disease detection via eye lens beta-amyloid scans.
Cognoptix is a Marlborough, Massachusetts, United States-based medical device company that develops the Sapphire II System, a non-invasive diagnostic tool designed to detect Alzheimer's disease early by scanning the human eye's lens for beta-amyloid deposits. The point-of-care technology provides clinicians with a lower-cost, office-based alternative to traditional PET scans, successfully identifying critical disease markers years before severe cognitive symptoms emerge in patients. Operating with a specialized team of four employees, the diagnostic firm currently generates just under $5 million in annual revenue. The healthcare enterprise has secured financial backing from institutional investors including Launchpad Venture Group through Series R fundraising and has presented its clinical advancements at major industry events such as the Sachs Neuroscience Innovation Forum under the leadership of Chief Executive Officer Susanne Wilke. Cognoptix was founded in January 2012 by medical researcher Lee E. Goldstein.
Cognoptix has raised $34.5M across 3 funding rounds.
Cognoptix has raised $34.5M in total across 3 funding rounds.
Cognoptix has raised $34.5M across 3 funding rounds. Most recently, it raised $15.0M Series D in September 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 30, 2014 | $15M Series D | Daniel Vlock, Gunnar Weikert | Launchpad Venture Group | Announced |
| Oct 23, 2008 | $18.5M Venture Round | — | Inventages, Launchpad Venture Group | Announced |
| Jan 1, 2007 | $1M Seed | — | O.g. Tech Partners | Announced |
Cognoptix has raised $34.5M in total across 3 funding rounds.
Cognoptix's investors include Daniel Vlock, Gunnar Weikert, Launchpad Venture Group, Inventages, O.G. Tech Partners.
Cognoptix is a medical technology company developing a non-invasive diagnostic platform for early detection of Alzheimer's disease (AD) through laser eye scanning.[1][2][3] Its Sapphire II System combines a fluorescent ophthalmic ointment that binds to beta-amyloid proteins in the eye lens with a compact laser scanner, enabling quick, in-office tests that detect amyloid deposits years before brain symptoms appear.[2][3][4] The company serves healthcare providers, clinicians, and pharmaceutical firms by addressing the limitations of costly PET scans—such as high expense, radiation exposure, and late-stage detection—potentially offering higher sensitivity for mild cognitive impairment (MCI).[1][2][4] With strong clinical results (85% sensitivity, 95% specificity vs. PET) from multicenter trials published in the *Journal of Alzheimer’s Disease & Other Dementias*, Cognoptix is advancing toward a pivotal study to support commercialization.[2][4]
Cognoptix, founded in 2019 and based in Marlborough, Massachusetts (previously known as Neuroptix), emerged from licensed technology developed at the University of California, San Diego (UCSD).[1][5] The company exclusively licensed color-coded markers for beta-amyloid detection, building on research showing amyloid aggregation in the eye lens as an early AD biomarker.[3][5] Key leadership includes President and CEO Susanne Wilke, steering development from early clinical validation to pre-pivotal trials.[2] Pivotal moments include multicenter trials demonstrating correlation with PET brain imaging and superior early detection potential, positioning it for partnerships with pharma for drug trials.[2][3][4]
Cognoptix rides the wave of early AD diagnostics and preventive neurology, fueled by surging demand for biomarkers amid an aging population (e.g., 5+ million US AD cases) and emerging anti-amyloid therapies like lecanemab.[2][3] Timing aligns with regulatory shifts favoring non-invasive tools and pharma's need for efficient trial enrichment, where eye scans could reduce PET dependency and accelerate drug development.[3][4] Market tailwinds include biotech innovation in neurodegeneration (competitors like Neurotrack, Darmiyan focus on digital/AI alternatives) and healthcare pushes for scalable screening to enable intervention before irreversible damage.[1] By democratizing access, Cognoptix influences the ecosystem, potentially boosting trial success rates and integrating into primary care workflows.
Cognoptix nears commercialization via its pivotal study, replicating pre-pivotal MCI sensitivity to secure FDA clearance and pharma licensing deals.[2][3] Trends like AI-enhanced neurodegeneration tools and combination therapies will amplify its role, possibly expanding to monitor treatment efficacy amid rising AD drug pipelines. Its influence could grow by transforming AD from late-diagnosis crisis to proactive screening standard, fulfilling the promise of a simple eye scan as the ultimate early warning system.[3][4]